Calliditas Therapeutics Ab's Revenue per employee grew on a trailing twelve month basis to $ 2,437,723, above the company average. Within the Healthcare sector Employees of 53 other companies have achieved higher revenue per employee. While Calliditas Therapeutics Ab's total ranking has deteriorated compared to the previous quarter from 309 to 704. Calliditas Therapeutics Ab has 85 employees.
In a significant move to strengthen its financial position, Calliditas Therapeutics AB (Nasdaq: CALT) and (Nasdaq Stockholm: CALTX) have recently announced the successful refinancing of its existing term loan. The company has secured a Euro 92 million senior secured facility with funds managed by Athyrium Capital Management, LP (Athyrium). This strategic collaboration aims to fuel the future growth prospects of Calliditas in the pharmaceutical industry. Rising Productivity and Revenue Per Employee: Calliditas Therapeutics has been experiencing exceptional growth in terms of revenue per employee. Over the trailing twelve months, the company s revenue per employee has reached an all-time high, reflecting the productivity and effectiveness of their workforce. This achievement underscores Calliditas commitment to driving efficiency and maximizing results.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
